2021 Annual Meeting Biologics Access Pass-Questions and Answers: Role of Biologics in Sports Medicine

Questions and Answers: Role of Biologics in Sports Medicine

Video Transcription

Video Summary

The panel discussed addressing patient misinformation about biologic treatments, emphasizing thorough education and managing unrealistic expectations by providing scientific literature and transparent communication. They highlighted the prevalence of off-label uses and the responsibility of physicians to inform patients honestly, even if patients pursue unadvised treatments. Regarding regulatory issues, recent FDA guidance warns against unauthorized use of biologics marketed under misleading claims, especially involving INDs, IRBs, and Q-code billing scams, cautioning providers about legal risks and website claims. On treatment options, percutaneous tenotomy was noted as a promising, insurance-covered alternative for tendinopathies, though comparative studies with PRP are scarce.

Asset Caption

Louis McIntyre, MD; C Thomas Vangsness, MD; Claude Moorman, MD; Craig Mauro, MD

Keywords

patient misinformation

biologic treatments

FDA guidance

off-label use

percutaneous tenotomy